Akebia Therapeutics reported $35.04M in Gross Profit on Sales for its third fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 104M 19M
Akebia Therapeutics AKBA:US $ 35.04M 4.07M
Alexion Pharmaceuticals ALXN:US $ 1299.7M 33.4M
Alnylam Pharmaceuticals ALNY:US $ 104.06M 20.02M
Amgen AMGN:US $ 4718M 70M
AstraZeneca AZN:LN 5.22B 90M
Bayer BAYN:GR 603.6M 215.3M
Biomarin Pharmaceutical BMRN:US $ 331.52M 59.18M
Exelixis EXEL:US $ 250M 33M
Fresenius Medical Care FME:GR € 1436M 26M
GlaxoSmithKline GSK:LN 519.5M 111.4M
Intercept Pharmaceuticals ICPT:US $ 75.37M 3.57M
Ironwood Pharmaceuticals IRWD:US $ 103.47M 14.04M
Johnson & Johnson JNJ:US $ 14142M 2363M
Opko Health OPK:US $ 155.29M 16.74M
Ptc Therapeutics PTCT:US $ 69.94M 5.76M
Regeneron Pharmaceuticals REGN:US $ 1676.5M 65.6M
Sarepta Therapeutics SRPT:US $ 124M 23M
Seattle Genetics SGEN:US $ 983.44M 753.68M
Vanda Pharmaceuticals VNDA:US $ 56.36M 3.57M